Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the efficacy and safety of docetaxel plus bevacizumab in patients
with pretreated, advanced non small cell lung cancer (NSCLC).